atopaxar
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
doi:10.1160/TH12-06-0389 Thromb Haemost 2013; 109: 164–167 Dear Sirs, Protease-activated receptors (PARs) are a family of four G…
Background: Meta-analysis for the efficacy and safety data of thrombin-receptor antagonist (TRA) based on patients with acute…
Antiplatelet drugs are the cornerstone in prevention and treatment of atherothrombotic vessel occlusions, i.e. myocardial…
Vorapaxar, a first-in-class, oral antagonist of protease-activated receptor 1 (PAR-1), inhibits thrombin-induced platelet…
Significant progress was achieved in the search of a thrombin receptor antagonist as a novel antithrombotic treatment since the…